Brawn Biotech Limited has submitted a regulatory disclosure to BSE Limited regarding an upcoming board meeting. The meeting of the Board of Directors is scheduled to be held on Thursday, August 13, 2026. The primary agenda item is to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2026 (Q1 FY27).
The disclosure confirms that the trading window for dealing in the company's securities remains closed for insiders, as previously intimated in a letter dated June 25, 2026. The closure is in compliance with the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders. The trading window will reopen on August 16, 2026, following the 48-hour period after the results announcement.